US7732464B2 - Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists - Google Patents
Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists Download PDFInfo
- Publication number
- US7732464B2 US7732464B2 US10/560,486 US56048604A US7732464B2 US 7732464 B2 US7732464 B2 US 7732464B2 US 56048604 A US56048604 A US 56048604A US 7732464 B2 US7732464 B2 US 7732464B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- formula
- substituted
- hydroxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 0 *C1=C([2*])C([1*])=C(C(=O)N([H])CC2CCN(*)CC2)C=C1[4*].CC Chemical compound *C1=C([2*])C([1*])=C(C(=O)N([H])CC2CCN(*)CC2)C=C1[4*].CC 0.000 description 20
- COJOQIBKKJIHLX-UHFFFAOYSA-N CCCCC1=CC(O)=NO1 Chemical compound CCCCC1=CC(O)=NO1 COJOQIBKKJIHLX-UHFFFAOYSA-N 0.000 description 14
- ZMVUPGJZKHFFSM-UHFFFAOYSA-N CCCCCN1C=CC(O)=N1 Chemical compound CCCCCN1C=CC(O)=N1 ZMVUPGJZKHFFSM-UHFFFAOYSA-N 0.000 description 12
- GAGALXYDHSHHCD-DTWKUNHWSA-N CC(C)(C)OC(=O)N1CC[C@@H](CN)[C@H](O)C1 Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](CN)[C@H](O)C1 GAGALXYDHSHHCD-DTWKUNHWSA-N 0.000 description 3
- JAHCQVVOKAFXQU-UHFFFAOYSA-N CCCC1=NN=NN1 Chemical compound CCCC1=NN=NN1 JAHCQVVOKAFXQU-UHFFFAOYSA-N 0.000 description 3
- PLHJRIBZRHLPLB-UHFFFAOYSA-N CCCCC1=NN=NN1 Chemical compound CCCCC1=NN=NN1 PLHJRIBZRHLPLB-UHFFFAOYSA-N 0.000 description 3
- OKIYPFZZDQLNMP-UHFFFAOYSA-N CCCCCC1=NN=NN1 Chemical compound CCCCCC1=NN=NN1 OKIYPFZZDQLNMP-UHFFFAOYSA-N 0.000 description 3
- NOHNSECEKFOVGT-UHFFFAOYSA-N CCCCN1CC(=O)NC1=O Chemical compound CCCCN1CC(=O)NC1=O NOHNSECEKFOVGT-UHFFFAOYSA-N 0.000 description 3
- NBVWGXYHHOOUAV-UHFFFAOYSA-N CCCCN1N=NNC1=O Chemical compound CCCCN1N=NNC1=O NBVWGXYHHOOUAV-UHFFFAOYSA-N 0.000 description 3
- NBCZHTDZQNDOOO-GXTWGEPZSA-N CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCCOC2=C1 Chemical compound CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCCOC2=C1 NBCZHTDZQNDOOO-GXTWGEPZSA-N 0.000 description 2
- BMZZKTFAMMCUFK-DOTOQJQBSA-N CC1=CC=C(C(=O)NC[C@@H]2CCN(CCC#N)C[C@H]2O)C2=C1OCCCO2 Chemical compound CC1=CC=C(C(=O)NC[C@@H]2CCN(CCC#N)C[C@H]2O)C2=C1OCCCO2 BMZZKTFAMMCUFK-DOTOQJQBSA-N 0.000 description 2
- IERWMZNDJGYCIA-UHFFFAOYSA-N CCCCCN1CCOCC1 Chemical compound CCCCCN1CCOCC1 IERWMZNDJGYCIA-UHFFFAOYSA-N 0.000 description 2
- JGRZXIYYVNWEBI-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=C(F)C=C1 Chemical compound COC(=O)C1=C2OCCCOC2=C(F)C=C1 JGRZXIYYVNWEBI-UHFFFAOYSA-N 0.000 description 2
- YIEXHCODYBKAAZ-DOTOQJQBSA-N CO[C@@H]1CN(C(=O)OC(C)(C)C)CC[C@H]1COS(=O)(=O)C1=CC=C(C)C=C1 Chemical compound CO[C@@H]1CN(C(=O)OC(C)(C)C)CC[C@H]1COS(=O)(=O)C1=CC=C(C)C=C1 YIEXHCODYBKAAZ-DOTOQJQBSA-N 0.000 description 2
- FTTNAAJCPYOXNH-GXFFZTMASA-N O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=CC(Cl)=C1 Chemical compound O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=CC(Cl)=C1 FTTNAAJCPYOXNH-GXFFZTMASA-N 0.000 description 2
- FYKPGIMFHYEWIL-JKSUJKDBSA-N CC(C)(C)OC(=O)N1CC[C@@H](CNCC2=CC=CC=C2)[C@H](O)C1 Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](CNCC2=CC=CC=C2)[C@H](O)C1 FYKPGIMFHYEWIL-JKSUJKDBSA-N 0.000 description 1
- ICPIYUPBXYOHKH-GXTWGEPZSA-N CC1=C2OCCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2O)C=C1 Chemical compound CC1=C2OCCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2O)C=C1 ICPIYUPBXYOHKH-GXTWGEPZSA-N 0.000 description 1
- AGSKKUWEJDDAPT-UHFFFAOYSA-N CC1=C2OCCCOC2=C(C(=O)O)C=C1 Chemical compound CC1=C2OCCCOC2=C(C(=O)O)C=C1 AGSKKUWEJDDAPT-UHFFFAOYSA-N 0.000 description 1
- PYNQQJSYQZCVHP-WCQYABFASA-N CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCOC2=C1 Chemical compound CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCOC2=C1 PYNQQJSYQZCVHP-WCQYABFASA-N 0.000 description 1
- MFXOGNHSBWMQOH-UHFFFAOYSA-N CC1=CC(C(=O)O)=C2OCCCOC2=C1 Chemical compound CC1=CC(C(=O)O)=C2OCCCOC2=C1 MFXOGNHSBWMQOH-UHFFFAOYSA-N 0.000 description 1
- GXGDXFRDPYBOEK-UHFFFAOYSA-N CC1=CC(C(=O)O)=C2OCCOC2=C1 Chemical compound CC1=CC(C(=O)O)=C2OCCOC2=C1 GXGDXFRDPYBOEK-UHFFFAOYSA-N 0.000 description 1
- FQRBZWYLHMZDHR-DOTOQJQBSA-N CC1=CC2=C(OCCCO2)C(C(=O)NC[C@@H]2CCN(C(=O)OC(C)(C)C)C[C@H]2O)=C1 Chemical compound CC1=CC2=C(OCCCO2)C(C(=O)NC[C@@H]2CCN(C(=O)OC(C)(C)C)C[C@H]2O)=C1 FQRBZWYLHMZDHR-DOTOQJQBSA-N 0.000 description 1
- FROVSSUKGYOOPM-DOTOQJQBSA-N CC1=CC2=C(OCCCO2)C(C(=O)NC[C@@H]2CCN(CCC#N)C[C@H]2O)=C1 Chemical compound CC1=CC2=C(OCCCO2)C(C(=O)NC[C@@H]2CCN(CCC#N)C[C@H]2O)=C1 FROVSSUKGYOOPM-DOTOQJQBSA-N 0.000 description 1
- PRNKCGNDBWEOJY-JYFHCDHNSA-N CC1=CC2=C(OCCCO2)C(C(=O)NC[C@@H]2CCN(CCCC3=CC(OCC4=CC=CC=C4)=NO3)C[C@H]2O)=C1 Chemical compound CC1=CC2=C(OCCCO2)C(C(=O)NC[C@@H]2CCN(CCCC3=CC(OCC4=CC=CC=C4)=NO3)C[C@H]2O)=C1 PRNKCGNDBWEOJY-JYFHCDHNSA-N 0.000 description 1
- POOCDTKATJYNHL-UHFFFAOYSA-N CCCCN1C(=O)CNC1=O Chemical compound CCCCN1C(=O)CNC1=O POOCDTKATJYNHL-UHFFFAOYSA-N 0.000 description 1
- LMRKVKPRHROQRR-UHFFFAOYSA-N CCCCN1CCOCC1 Chemical compound CCCCN1CCOCC1 LMRKVKPRHROQRR-UHFFFAOYSA-N 0.000 description 1
- KRCUVYXUSPCHLQ-AZUAARDMSA-N CCOC(=O)CNCCCN1CC[C@@H](CNC(=O)C2=C3OCCCOC3=C(C)C=C2)[C@H](O)C1 Chemical compound CCOC(=O)CNCCCN1CC[C@@H](CNC(=O)C2=C3OCCCOC3=C(C)C=C2)[C@H](O)C1 KRCUVYXUSPCHLQ-AZUAARDMSA-N 0.000 description 1
- PIPVKXQKYMZZRG-AZUAARDMSA-N CCOC(=O)CNCCCN1CC[C@@H](CNC(=O)C2=C3OCCCOC3=CC(C)=C2)[C@H](O)C1 Chemical compound CCOC(=O)CNCCCN1CC[C@@H](CNC(=O)C2=C3OCCCOC3=CC(C)=C2)[C@H](O)C1 PIPVKXQKYMZZRG-AZUAARDMSA-N 0.000 description 1
- KVVWRQCRBPHVDW-QFBILLFUSA-N CCOC(=O)CNCCCN1CC[C@@H](CNC(=O)C2=C3OCCCOC3=CC(Cl)=C2)[C@H](O)C1 Chemical compound CCOC(=O)CNCCCN1CC[C@@H](CNC(=O)C2=C3OCCCOC3=CC(Cl)=C2)[C@H](O)C1 KVVWRQCRBPHVDW-QFBILLFUSA-N 0.000 description 1
- VEDBVQXMWUUNEP-UHFFFAOYSA-N COC(=O)C1=C(O)C(O)=C(Br)C(Cl)=C1 Chemical compound COC(=O)C1=C(O)C(O)=C(Br)C(Cl)=C1 VEDBVQXMWUUNEP-UHFFFAOYSA-N 0.000 description 1
- GANYVNTZFRNKCD-UHFFFAOYSA-N COC(=O)C1=C(O)C(O)=C(Cl)C(Cl)=C1 Chemical compound COC(=O)C1=C(O)C(O)=C(Cl)C(Cl)=C1 GANYVNTZFRNKCD-UHFFFAOYSA-N 0.000 description 1
- MKJRJALSOXCYMX-UHFFFAOYSA-N COC(=O)C1=C(O)C(O)=C(F)C=C1 Chemical compound COC(=O)C1=C(O)C(O)=C(F)C=C1 MKJRJALSOXCYMX-UHFFFAOYSA-N 0.000 description 1
- PWEIBNGOTOLRMO-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 Chemical compound COC(=O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 PWEIBNGOTOLRMO-UHFFFAOYSA-N 0.000 description 1
- RROHLRMSQCHMOG-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=C(C)C=C1 Chemical compound COC(=O)C1=C2OCCCOC2=C(C)C=C1 RROHLRMSQCHMOG-UHFFFAOYSA-N 0.000 description 1
- JLXLLSZKWCVTKC-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=C(OC)C=C1 Chemical compound COC(=O)C1=C2OCCCOC2=C(OC)C=C1 JLXLLSZKWCVTKC-UHFFFAOYSA-N 0.000 description 1
- IWFINGUMISJZLN-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=CC(Br)=C1 Chemical compound COC(=O)C1=C2OCCCOC2=CC(Br)=C1 IWFINGUMISJZLN-UHFFFAOYSA-N 0.000 description 1
- GVXDYTPYBCUZRV-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=CC(C)=C1 Chemical compound COC(=O)C1=C2OCCCOC2=CC(C)=C1 GVXDYTPYBCUZRV-UHFFFAOYSA-N 0.000 description 1
- RKDOPIWDYCQXNR-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=CC(Cl)=C1 Chemical compound COC(=O)C1=C2OCCCOC2=CC(Cl)=C1 RKDOPIWDYCQXNR-UHFFFAOYSA-N 0.000 description 1
- WAWKBWVQNLMYGZ-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=CC(F)=C1 Chemical compound COC(=O)C1=C2OCCCOC2=CC(F)=C1 WAWKBWVQNLMYGZ-UHFFFAOYSA-N 0.000 description 1
- HVIWIEXTWBIPFA-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=CC(N)=C1 Chemical compound COC(=O)C1=C2OCCCOC2=CC(N)=C1 HVIWIEXTWBIPFA-UHFFFAOYSA-N 0.000 description 1
- QNEWHPHXIPSPBV-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=CC([N+]#N)=C1 Chemical compound COC(=O)C1=C2OCCCOC2=CC([N+]#N)=C1 QNEWHPHXIPSPBV-UHFFFAOYSA-N 0.000 description 1
- KKFMVSMQILOCQC-UHFFFAOYSA-N COC(=O)C1=C2OCCCOC2=CC([N+](=O)[O-])=C1 Chemical compound COC(=O)C1=C2OCCCOC2=CC([N+](=O)[O-])=C1 KKFMVSMQILOCQC-UHFFFAOYSA-N 0.000 description 1
- PWJJSYAASLDBIU-UHFFFAOYSA-N COC(=O)C1=C2OCCOC2=CC(C#N)=C1 Chemical compound COC(=O)C1=C2OCCOC2=CC(C#N)=C1 PWJJSYAASLDBIU-UHFFFAOYSA-N 0.000 description 1
- BAYUDZZMCZBIMD-UHFFFAOYSA-N COC(=O)C1=C2OCCOC2=CC(C)=C1 Chemical compound COC(=O)C1=C2OCCOC2=CC(C)=C1 BAYUDZZMCZBIMD-UHFFFAOYSA-N 0.000 description 1
- DPLLNNPRZMIPTH-UHFFFAOYSA-N COC(=O)C1=C2OCCOC2=CC(N)=C1 Chemical compound COC(=O)C1=C2OCCOC2=CC(N)=C1 DPLLNNPRZMIPTH-UHFFFAOYSA-N 0.000 description 1
- VWINLHLLQKBVRG-UHFFFAOYSA-N COC(=O)C1=C2OCCOC2=CC([N+](=O)[O-])=C1 Chemical compound COC(=O)C1=C2OCCOC2=CC([N+](=O)[O-])=C1 VWINLHLLQKBVRG-UHFFFAOYSA-N 0.000 description 1
- WZGPQCNJPKFHMG-UHFFFAOYSA-N COC(=O)C1=CC(Cl)=C(Cl)C2=C1OCCCO2 Chemical compound COC(=O)C1=CC(Cl)=C(Cl)C2=C1OCCCO2 WZGPQCNJPKFHMG-UHFFFAOYSA-N 0.000 description 1
- FVNJDZAEVSFUAG-UHFFFAOYSA-N COC(=O)C1=CC(F)=CC2=C1OCCO2 Chemical compound COC(=O)C1=CC(F)=CC2=C1OCCO2 FVNJDZAEVSFUAG-UHFFFAOYSA-N 0.000 description 1
- NHIPMIVYDOUBTF-UHFFFAOYSA-N COC(=O)C1=CC([N+]#N)=CC2=C1OCCO2 Chemical compound COC(=O)C1=CC([N+]#N)=CC2=C1OCCO2 NHIPMIVYDOUBTF-UHFFFAOYSA-N 0.000 description 1
- UFLHCEVMCRXURC-WCQYABFASA-N COC1=C2OCCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2O)C=C1 Chemical compound COC1=C2OCCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2O)C=C1 UFLHCEVMCRXURC-WCQYABFASA-N 0.000 description 1
- KFVFUHFTQVMYBU-SWLSCSKDSA-N COC1=C2OCCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2OC)C=C1 Chemical compound COC1=C2OCCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2OC)C=C1 KFVFUHFTQVMYBU-SWLSCSKDSA-N 0.000 description 1
- PRQGOKDBKHUBFN-UHFFFAOYSA-N COC1=C2OCCCOC2=C(C(=O)O)C=C1 Chemical compound COC1=C2OCCCOC2=C(C(=O)O)C=C1 PRQGOKDBKHUBFN-UHFFFAOYSA-N 0.000 description 1
- MCPQDZJNFOLYJU-CMPLNLGQSA-N COC1=C2OCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2O)C=C1 Chemical compound COC1=C2OCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2O)C=C1 MCPQDZJNFOLYJU-CMPLNLGQSA-N 0.000 description 1
- MWFQLYPQAMVIJO-SMDDNHRTSA-N COC1=C2OCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2OC)C=C1 Chemical compound COC1=C2OCCOC2=C(C(=O)NC[C@@H]2CCNC[C@H]2OC)C=C1 MWFQLYPQAMVIJO-SMDDNHRTSA-N 0.000 description 1
- WXQMQAMXMZTBAB-VHSXEESVSA-N CO[C@@H]1CN(C(=O)OC(C)(C)C)CC[C@H]1CN Chemical compound CO[C@@H]1CN(C(=O)OC(C)(C)C)CC[C@H]1CN WXQMQAMXMZTBAB-VHSXEESVSA-N 0.000 description 1
- UDPWICLUZCFKJM-GXFFZTMASA-N CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 Chemical compound CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 UDPWICLUZCFKJM-GXFFZTMASA-N 0.000 description 1
- BXZPTFKHFAWVKQ-GXFFZTMASA-N CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=C(Cl)C(Cl)=C1 Chemical compound CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=C(Cl)C(Cl)=C1 BXZPTFKHFAWVKQ-GXFFZTMASA-N 0.000 description 1
- YRCRKDSUFQEABG-XJKSGUPXSA-N CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(C#N)=C1 Chemical compound CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(C#N)=C1 YRCRKDSUFQEABG-XJKSGUPXSA-N 0.000 description 1
- UGBXYBZCRZZMMP-XJKSGUPXSA-N CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(C)=C1 Chemical compound CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(C)=C1 UGBXYBZCRZZMMP-XJKSGUPXSA-N 0.000 description 1
- XJPSTHJRNRGAJG-XHDPSFHLSA-N CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(Cl)=C1 Chemical compound CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(Cl)=C1 XJPSTHJRNRGAJG-XHDPSFHLSA-N 0.000 description 1
- GVUVGQPKSYCQFI-XHDPSFHLSA-N CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(F)=C1 Chemical compound CO[C@@H]1CNCC[C@H]1CNC(=O)C1=C2OCCCOC2=CC(F)=C1 GVUVGQPKSYCQFI-XHDPSFHLSA-N 0.000 description 1
- RCAPSCAJBGZIRE-UHFFFAOYSA-N ClCCCC1=CC(OCC2=CC=CC=C2)=NO1 Chemical compound ClCCCC1=CC(OCC2=CC=CC=C2)=NO1 RCAPSCAJBGZIRE-UHFFFAOYSA-N 0.000 description 1
- GFJGKGDALQDTQN-UHFFFAOYSA-N ClCCCC1=NN=NN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound ClCCCC1=NN=NN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 GFJGKGDALQDTQN-UHFFFAOYSA-N 0.000 description 1
- BXZOZWOPWFDFRM-GXTWGEPZSA-N N#CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCCOC2=C1 Chemical compound N#CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCCOC2=C1 BXZOZWOPWFDFRM-GXTWGEPZSA-N 0.000 description 1
- CWBXJGHAQUYZRZ-WCQYABFASA-N N#CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCOC2=C1 Chemical compound N#CC1=CC(C(=O)NC[C@@H]2CCNC[C@H]2O)=C2OCCOC2=C1 CWBXJGHAQUYZRZ-WCQYABFASA-N 0.000 description 1
- UNBWMTDQPHYMGC-UHFFFAOYSA-N N#CC1=CC(C(=O)O)=C2OCCCOC2=C1 Chemical compound N#CC1=CC(C(=O)O)=C2OCCCOC2=C1 UNBWMTDQPHYMGC-UHFFFAOYSA-N 0.000 description 1
- QPLDPOAHODHBEP-UHFFFAOYSA-N N#CC1=CC(C(=O)O)=C2OCCOC2=C1 Chemical compound N#CC1=CC(C(=O)O)=C2OCCOC2=C1 QPLDPOAHODHBEP-UHFFFAOYSA-N 0.000 description 1
- PFJJVHOFOHPNEL-XJKSGUPXSA-N N#CCCN1CC[C@@H](CNC(=O)C2=CC(Cl)=CC3=C2OCCCO3)[C@H](O)C1 Chemical compound N#CCCN1CC[C@@H](CNC(=O)C2=CC(Cl)=CC3=C2OCCCO3)[C@H](O)C1 PFJJVHOFOHPNEL-XJKSGUPXSA-N 0.000 description 1
- SEGSNXACATZSCU-UHFFFAOYSA-N NCC(CC1)CCN1I Chemical compound NCC(CC1)CCN1I SEGSNXACATZSCU-UHFFFAOYSA-N 0.000 description 1
- PHYSESIYNGHBBU-IPZQJPLYSA-N O=C(NC[C@@H]1CCN(CCCC2=NN=NN2C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C[C@H]1O)C1=C2OCCCOC2=CC(Cl)=C1 Chemical compound O=C(NC[C@@H]1CCN(CCCC2=NN=NN2C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C[C@H]1O)C1=C2OCCCOC2=CC(Cl)=C1 PHYSESIYNGHBBU-IPZQJPLYSA-N 0.000 description 1
- SEUSTOGODJNFFI-JOYOIKCWSA-N O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 Chemical compound O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 SEUSTOGODJNFFI-JOYOIKCWSA-N 0.000 description 1
- LOKHLEZPSFYMHE-JOYOIKCWSA-N O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=C(Cl)C(Cl)=C1 Chemical compound O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=C(Cl)C(Cl)=C1 LOKHLEZPSFYMHE-JOYOIKCWSA-N 0.000 description 1
- PFXAXRJUZBVEAF-GXFFZTMASA-N O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=C(F)C=C1 Chemical compound O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=C(F)C=C1 PFXAXRJUZBVEAF-GXFFZTMASA-N 0.000 description 1
- YBMSCSKTFCGSBA-GXFFZTMASA-N O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=CC(F)=C1 Chemical compound O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCCOC2=CC(F)=C1 YBMSCSKTFCGSBA-GXFFZTMASA-N 0.000 description 1
- JLBYESTYHHUEOG-JOYOIKCWSA-N O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCOC2=CC(F)=C1 Chemical compound O=C(NC[C@@H]1CCNC[C@H]1O)C1=C2OCCOC2=CC(F)=C1 JLBYESTYHHUEOG-JOYOIKCWSA-N 0.000 description 1
- IIFIBQCNFXRXIR-UHFFFAOYSA-N O=C(O)C1=C(O)C(O)=C(F)C=C1 Chemical compound O=C(O)C1=C(O)C(O)=C(F)C=C1 IIFIBQCNFXRXIR-UHFFFAOYSA-N 0.000 description 1
- FOGZBVLDLVRKSH-UHFFFAOYSA-N O=C(O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 Chemical compound O=C(O)C1=C2OCCCOC2=C(Br)C(Cl)=C1 FOGZBVLDLVRKSH-UHFFFAOYSA-N 0.000 description 1
- WOCNVZQOPFNMEO-UHFFFAOYSA-N O=C(O)C1=C2OCCCOC2=C(F)C=C1 Chemical compound O=C(O)C1=C2OCCCOC2=C(F)C=C1 WOCNVZQOPFNMEO-UHFFFAOYSA-N 0.000 description 1
- FFIZOJMFPFGOOT-UHFFFAOYSA-N O=C(O)C1=C2OCCCOC2=CC(Br)=C1 Chemical compound O=C(O)C1=C2OCCCOC2=CC(Br)=C1 FFIZOJMFPFGOOT-UHFFFAOYSA-N 0.000 description 1
- JROQKWFJVNZEET-UHFFFAOYSA-N O=C(O)C1=C2OCCCOC2=CC(Cl)=C1 Chemical compound O=C(O)C1=C2OCCCOC2=CC(Cl)=C1 JROQKWFJVNZEET-UHFFFAOYSA-N 0.000 description 1
- YKUNSLMPCUJSKT-UHFFFAOYSA-N O=C(O)C1=C2OCCCOC2=CC(F)=C1 Chemical compound O=C(O)C1=C2OCCCOC2=CC(F)=C1 YKUNSLMPCUJSKT-UHFFFAOYSA-N 0.000 description 1
- AWBYCAAPBSMPET-UHFFFAOYSA-N O=C(O)C1=CC(Cl)=C(Cl)C2=C1OCCCO2 Chemical compound O=C(O)C1=CC(Cl)=C(Cl)C2=C1OCCCO2 AWBYCAAPBSMPET-UHFFFAOYSA-N 0.000 description 1
- TXGMTNKTEATJLN-UHFFFAOYSA-N O=C(O)C1=CC(F)=CC2=C1OCCO2 Chemical compound O=C(O)C1=CC(F)=CC2=C1OCCO2 TXGMTNKTEATJLN-UHFFFAOYSA-N 0.000 description 1
- MYAFQYGZQSJOHS-UHFFFAOYSA-N OC1=NN(CCCCCl)C=C1 Chemical compound OC1=NN(CCCCCl)C=C1 MYAFQYGZQSJOHS-UHFFFAOYSA-N 0.000 description 1
- AQFOJTASHNDMBV-UHFFFAOYSA-N OC1=NOC(CCCCl)=C1 Chemical compound OC1=NOC(CCCCl)=C1 AQFOJTASHNDMBV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0350240 | 2003-06-19 | ||
| EPPCT/EP03/50240 | 2003-06-19 | ||
| PCT/EP2004/006273 WO2005003124A1 (fr) | 2003-06-19 | 2004-06-10 | 4-(aminomethyl)-piperidine benzamides substitues par des heterocycles, utilises comme antagonistes des recepteurs 5ht4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20070197600A1 US20070197600A1 (en) | 2007-08-23 |
| US7732464B2 true US7732464B2 (en) | 2010-06-08 |
Family
ID=33560737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/560,486 Expired - Fee Related US7732464B2 (en) | 2003-06-19 | 2004-06-10 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7732464B2 (fr) |
| EP (1) | EP1638961B1 (fr) |
| JP (1) | JP4767844B2 (fr) |
| KR (1) | KR101151643B1 (fr) |
| AT (1) | ATE449093T1 (fr) |
| AU (1) | AU2004254190B2 (fr) |
| CA (1) | CA2528642C (fr) |
| DE (1) | DE602004024200D1 (fr) |
| EA (1) | EA008514B1 (fr) |
| ES (1) | ES2336448T3 (fr) |
| WO (1) | WO2005003124A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0901487D0 (en) * | 2009-01-30 | 2009-03-11 | Movetis N V | Asthma Therapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4186135A (en) * | 1976-08-04 | 1980-01-29 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation |
| WO1993005038A1 (fr) | 1991-09-12 | 1993-03-18 | Smithkline Beecham Plc | Antagonistes de recepteurs 5-hydroxytriptamine 4 |
| WO2000037461A1 (fr) | 1998-12-22 | 2000-06-29 | Janssen Pharmaceutica N.V. | 4-(aminomethyl)-piperidine benzamides permettant de traiter les troubles gastro-intestinaux |
| WO2004017960A1 (fr) * | 2002-08-14 | 2004-03-04 | Janssen Pharmaceutica N.V. | Traitement de symptomes des voies urinaires basses lies a une hyperactivite de la vessie chez l'homme et la femme |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
| TW548103B (en) * | 1997-07-11 | 2003-08-21 | Janssen Pharmaceutica Nv | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| CA2340952C (fr) * | 1998-09-10 | 2009-12-08 | F. Hoffmann-La Roche Ag | Dihydrobenzodioxine carboxamide et derives de cetone utilises comme antagonistes du recepteur 5-ht4 |
-
2004
- 2004-06-10 EA EA200600059A patent/EA008514B1/ru not_active IP Right Cessation
- 2004-06-10 CA CA2528642A patent/CA2528642C/fr not_active Expired - Fee Related
- 2004-06-10 EP EP04739776A patent/EP1638961B1/fr active Active
- 2004-06-10 DE DE602004024200T patent/DE602004024200D1/de active Active
- 2004-06-10 ES ES04739776T patent/ES2336448T3/es active Active
- 2004-06-10 AT AT04739776T patent/ATE449093T1/de not_active IP Right Cessation
- 2004-06-10 WO PCT/EP2004/006273 patent/WO2005003124A1/fr active Application Filing
- 2004-06-10 US US10/560,486 patent/US7732464B2/en not_active Expired - Fee Related
- 2004-06-10 JP JP2006515879A patent/JP4767844B2/ja not_active Expired - Fee Related
- 2004-06-10 AU AU2004254190A patent/AU2004254190B2/en not_active Ceased
-
2005
- 2005-12-09 KR KR1020057023765A patent/KR101151643B1/ko active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4186135A (en) * | 1976-08-04 | 1980-01-29 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation |
| WO1993005038A1 (fr) | 1991-09-12 | 1993-03-18 | Smithkline Beecham Plc | Antagonistes de recepteurs 5-hydroxytriptamine 4 |
| WO2000037461A1 (fr) | 1998-12-22 | 2000-06-29 | Janssen Pharmaceutica N.V. | 4-(aminomethyl)-piperidine benzamides permettant de traiter les troubles gastro-intestinaux |
| US6544997B1 (en) * | 1998-12-22 | 2003-04-08 | Janssen Pharmaceutica, N.V. | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| WO2004017960A1 (fr) * | 2002-08-14 | 2004-03-04 | Janssen Pharmaceutica N.V. | Traitement de symptomes des voies urinaires basses lies a une hyperactivite de la vessie chez l'homme et la femme |
Non-Patent Citations (2)
| Title |
|---|
| Patani et al. "Bioisoterism: a rational approach in drug design" Chem. Rev. v.96, p. 3147-3176 (1996). * |
| Search report for International Application No. PCT/EP/2004/006273. |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2528642A1 (fr) | 2005-01-13 |
| JP2006527714A (ja) | 2006-12-07 |
| ATE449093T1 (de) | 2009-12-15 |
| EA200600059A1 (ru) | 2006-06-30 |
| JP4767844B2 (ja) | 2011-09-07 |
| EP1638961B1 (fr) | 2009-11-18 |
| KR20060018260A (ko) | 2006-02-28 |
| DE602004024200D1 (de) | 2009-12-31 |
| AU2004254190B2 (en) | 2010-04-22 |
| EA008514B1 (ru) | 2007-06-29 |
| AU2004254190A1 (en) | 2005-01-13 |
| ES2336448T3 (es) | 2010-04-13 |
| CA2528642C (fr) | 2011-12-13 |
| KR101151643B1 (ko) | 2012-06-08 |
| US20070197600A1 (en) | 2007-08-23 |
| EP1638961A1 (fr) | 2006-03-29 |
| WO2005003124A1 (fr) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8334304B2 (en) | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | |
| US7638535B2 (en) | 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | |
| US7732464B2 (en) | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | |
| US7635706B2 (en) | 5HT4-antagonistic 4-(aminomethyl)-piperidine benzamides | |
| US7498347B2 (en) | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOSMANS, JEAN-PAUL RENE MARIE ANDRE;GIJSEN, HENRICUS JACOBUS MARIA;REEL/FRAME:017402/0267 Effective date: 20050926 Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN-CILAG;REEL/FRAME:017449/0300 Effective date: 20051006 Owner name: JANSSEN PHARMACEUTICA NV,BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOSMANS, JEAN-PAUL RENE MARIE ANDRE;GIJSEN, HENRICUS JACOBUS MARIA;REEL/FRAME:017402/0267 Effective date: 20050926 Owner name: JANSSEN PHARMACEUTICA NV,BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN-CILAG;REEL/FRAME:017449/0300 Effective date: 20051006 |
|
| AS | Assignment |
Owner name: JANSSEN-CILAG S.A., SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEVELLEC, LAURENCE ANNE;REEL/FRAME:019785/0392 Effective date: 20051006 Owner name: JANSSEN-CILAG S.A.,SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEVELLEC, LAURENCE ANNE;REEL/FRAME:019785/0392 Effective date: 20051006 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220608 |